This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Substance Withdrawal Syndrome
and you are
between 18 and 65
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This study will evaluate the potential therapeutic value of two neurosteroid treatments (DHEA and pregnenolone) in the treatment of tobacco withdrawal symptoms. This will include assessing whether these agents relieve craving for cigarettes elicited by exposure to a mildly stressful cognitive task. Pregnenolone (400 mg orally), DHEA (400 mg orally) and placebo will be administered one at each of the three sessions in a randomized order.

Provided treatments

  • : dehydroepiandrosterone (DHEA)
  • : pregnenolone
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT00900900. The sponsor of the trial is Jed E. Rose and it is looking for 22 volunteers for the current phase.
Official trial title:
The Effects of One-Time Pregnenolone, DHEA, Or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers